ADPT
Adaptive Biotechnologies Corp
$20.82
-0.68 (-3.16%)
At close · Jul 7
Market Cap
$3.33B
Shares
160,044,392
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.82
Open$21.37
Day$20.45–21.63
52W$9.96–22.80
Avg vol 30d3.2M
Short int7.6M · 4.8% float · 2.8d
Short vol38%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+31%
above
Price vs 50-day avg
+29%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
85%
mid-range
Momentum
relative strength
1-month return
+23%
trailing
6-month return
+14%
trailing
YTD return
+28%
this year
Relative strength
+6%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
6 of 295 funds reported for Jun 30 · net +20.5K sh shares · +1 new
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Falling
4.78% of float · ▼ -7.2% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
295 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+55%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$-48.9M
Balance sheet
$70.5M
net cash
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 5, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
MRD revenue
· full year 2026
Maintained
$260M – $270M
prior FY $276.98M
midpoint −4.3% Y/Y
Total company operating expenses, including cost of revenue
· full year 2026
Initiated
$350M – $360M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+31%
Bullish
Price vs 50-day avg
+29%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
85%
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Golden cross
50d $16 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
6 of 295 funds reported for Jun 30 · net +20.5K sh shares · +1 new
Insider flow
Distributing
Net -$4.3M over 90 days · 100% sells
Short interest
Falling
4.78% of float · ▼ -7.2% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
295 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $21 · 85%
52-wk high $23
vs 200-day avg +31%
vs 50-day avg +29%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| clonoSEQ test volume | 32,595 | first quarter of 2026 | — |
|
|
|||
| antigens in TCR antigen data set | 50,000 | Q1 2026 call | — |
| blood-based MRD volume contribution in multiple myeloma | 29% | Q1 2026 call | — |
| cash balance | $222M | Q1 2026 call | — |
| Clonaseek tests | 32,600 | Q1 2026 call | — |
| community volumes share of total testing | 35% | Q1 2026 call | — |
| HLA types in TCR antigen data set | 50 | Q1 2026 call | — |
| Immune medicine adjusted EBITDA non-GAAP | -$10.4M | Q1 2026 call | — |
| MRD adjusted EBITDA non-GAAP | $12.1M | Q1 2026 call | — |
| MRD pharma backlog | $254M | Q1 2026 call | — |
| ongoing interventional studies using MRD | 20 | Q1 2026 call | — |
| ordered clinicians | 5,000 | Q1 2026 call | — |
| RA patient samples received | 1,000 | Q1 2026 call | — |
| repeat orders fulfillment rate | 72% | Q1 2026 call | — |
| sequencing gross margin | 70% | Q1 2026 call | — |
| total company adjusted EBITDA non-GAAP | -$2.5M | Q1 2026 call | — |
| clonoSEQ tests delivered (full year) | 105,587 | Full Year 2025 | — |
| clonoSEQ tests delivered | 105,600 | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADPT
this stock
Adaptive Biotechnologies Corp
|
$3.33B | +28.2% | +54.8% | — | 4.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$189.58B | -11.9% | +0.4% | 28.0 | 1.2% |
|
DHR
Danaher Corp /De/
|
$135.02B | -14.8% | +8.5% | 36.8 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.83B | -17.9% | +10.4% | 40.9 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.28B | +22.8% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADPT | -1.9% | +23.2% | +14.0% | -2.9% | +28.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -2.8% | +21.8% | +6.5% | -3.1% | +18.6% |